MHRA (UK)Original article
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
RegulatoryXaggitin XL Prolonged-release TabletsNegative
AI Analysis
Summary
Martindale Pharma has notified the MHRA of a Class 4 manufacturing defect affecting batches of Xaggitin XL Prolonged-release Tablets, with incorrect tablet counts identified in bottles.
Outcome Details
Class 4 Medicines Defect Notification - incorrect tablet counts in bottles affecting multiple batches
Importance:4/10
Sentiment:
-0.60
Manufacturing DefectMHRAQuality IssueProduct Recall
Read the original article
Published by MHRA (UK) on July 20, 2026 1:01 PM